{"id":"W4388848431","doi":"10.1016/j.ejca.2023.113458","title":"First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Novartis Pharmaceuticals UK Limited; Chugai Pharmaceutical; Italfarmaco; Bristol-Myers Squibb; AstraZeneca; Symphogen; Sun Pharma; Eisai; Sanofi; Genentech; Pfizer; Novartis Pharmaceuticals Corporation; Daiichi-Sankyo","keywords":"Medicine; Rash; Nausea; KRAS; Adverse effect; Internal medicine; Gastroenterology; Dysgeusia; Pharmacology; Oncology; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002707008,0.0001697849,0.0002982683,0.0001639111,0.00006208179,0.00001962141,0.0001871546,0.00001909097,0.00001524576],"category_scores_gemma":[0.00003836903,0.0001183972,0.00003697995,0.0002534383,0.00003298331,0.00001980057,0.00004678709,0.0001498684,0.00000135592],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002866785,"about_ca_system_score_gemma":0.0001113018,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002802484,"about_ca_topic_score_gemma":0.001630795,"domain_scores_codex":[0.9985841,0.0001433895,0.0005469326,0.0002209533,0.0002763902,0.0002282367],"domain_scores_gemma":[0.9989804,0.000009319995,0.0004324183,0.000192287,0.0003043034,0.00008126503],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003942447,0.0009984439,0.782536,0.0001492477,0.0002460527,0.001386086,0.004928544,0.06887817,0.1337375,0.00001474721,0.0001342164,0.00304857],"study_design_scores_gemma":[0.04060112,0.03042758,0.6718444,0.003617334,0.0001483283,0.00005954324,0.005571973,0.0003423822,0.2431086,0.000008565727,0.003067077,0.0012031],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9992032,0.00006885923,0.00009249082,0.00001638045,0.0001076538,0.0002678453,0.00001165805,0.000005953872,0.0002259827],"genre_scores_gemma":[0.9993877,0.00002814916,0.000212916,0.00002399229,0.0001495966,0.00001285418,0.0000123995,0.00004537142,0.0001270182],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1106916,"threshold_uncertainty_score":0.4828098,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01382222958330516,"score_gpt":0.2650397317540292,"score_spread":0.2512175021707241,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}